Methylation profiling of brain metastasis tissue, cerebrospinal spinal (CSF) and plasma from patients with non-small cell lung cancer (NSCLC)

Brain metastasis tumor tissues obtained at the time of neurosurgical resection performed as part of routine clinical care were profiled alongside time-matched cell-free DNA (cfDNA) derived from CSF and plasma collected from the same patients.

Additional longitudinal CSF and plasma cfDNA samples collected at the time of clinically suspected leptomeningeal metastasis were also analyzed. All samples were assessed using the PredicineEPIC whole-genome methylation analysis platform to identify CpG sites covered by differentially methylated fragments (DMFs). These data support the development of liquid biopsy approaches for the detection, monitoring, and risk stratification of central nervous system disease in patients with NSCLC brain metastases.